+40%

est. 2Y upside i

InsurTechSeries A

Modern health insurance for dual income families

Rank

#2111

Sector

Insurtech

Est. Liquidity

~6Y

Data Quality

Data: Low

Healia is a high-risk early-stage bet where the equity structure is deeply unfavorable for a job-seeker receiving common stock today.

Last updated: May 5, 2026

Bull (20%)+300%

Healia closes a Series A at ~$20M post-money within 18 months on the strength of its 75%-margin TCO model, scaling to $4-5M ARR; a strategic acquisition or Series B at $50M+ in years 4-5 would yield roughly 10x on today's common-stock fair value after clearing the ~$4M liquidation preference stack. Within the strict 2-year window, value accrual comes almost entirely from the Series A re-price of common stock, not a realized exit.

Base (40%)+50%

Revenue grows to $2-3M by late 2026 but fundraising proves difficult in a compressed insurtech market, and Healia closes a bridge or modest Series A at $8-10M post-money valuation. Net of the $4M preference overhang, common stock sees limited paper appreciation of roughly 50% with no path to near-term liquidity.

Bear (40%)-100%

Healia fails to demonstrate sufficient growth velocity — with no disclosed YoY growth rate and unknown burn — to attract a clean Series A, exhausting runway by 2027. With $4.04M in investor liquidation preferences senior to every dollar of common stock, a distressed sale or wind-down returns $0 to employees.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

104%

Total funding of $4.04M equals 103.6% of the $3.9M analyst-estimated valuation, meaning preferred investors are owed more than the entire company is currently worth before common stock receives a single dollar in any liquidity event.

Dilution Risk

high

As a seed-stage company requiring multiple future financing rounds (Series A, B, and beyond) to reach enterprise scale, early employees should expect 40-60%+ cumulative dilution of their current grant before any liquidity event.

Secondary Liquidity

none

At a $3.9M valuation with no named institutional lead investor and 15 employees, there is effectively zero secondary market for Healia common stock in any timeframe relevant to this analysis.

View all 6 open roles at Healia →

Last updated: February 17, 2026

Questions to Ask at the Interview

Strategic questions based on Healia's data — designed to show you've done your homework.

  • 1

    “What is your current net revenue retention rate, and how many employer contracts have renewed or expanded their Total Care Option program beyond the initial term?”

  • 2

    “Can you walk me through the cap table and full liquidation preference stack — at what enterprise value does common stock first participate meaningfully in an exit given the $4M already raised?”

  • 3

    “What is your 18-month fundraising roadmap, who is your target Series A lead, and how many months of runway do you have at current burn?”

Community

Valuation Sentiment

Our model estimates +40% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.